[{"data":1,"prerenderedAt":171},["ShallowReactive",2],{"drug-vortioxetine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":52,"contraindications":78,"warnings":88,"renal":96,"monitoring":97,"interactions":98,"review":99,"examples":102,"atc":108,"iran":110,"usApproval":117,"links":123,"populations":137},"vortioxetine",1,{"fa":7,"en":8},"وورتیوکستین","Vortioxetine","nervous-system",{"fa":11,"en":12},"ضدافسردگی چندحالته","Multimodal antidepressant",[14],{"name":15,"market":16},"Trintellix","US",[18,19,20,7],"trintellix","brintellix","ترینتلیکس",[22,36,44],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-5","tablet","oral","5 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},5,"mg",false,[16],[33],{"source":34,"section":35},"fda-trintellix","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"tab-10","10 mg tablet",{"amount":40,"unit":29,"perUnit":24,"scored":30},10,[16],[43],{"source":34,"section":35},{"id":45,"form":24,"route":25,"label":46,"concentration":47,"markets":49,"refs":50},"tab-20","20 mg tablet",{"amount":48,"unit":29,"perUnit":24,"scored":30},20,[16],[51],{"source":34,"section":35},[53],{"id":54,"disease":54,"label":55,"population":58,"type":62,"unit":29,"dose":63,"refs":66,"notes":69},"mdd",{"fa":56,"en":57},"افسردگی اساسی — شروع ۱۰ mg یک بار در روز، سپس ۲۰ mg","Major depression — start 10 mg once daily, then 20 mg",{"minAge":59},{"value":60,"unit":61},18,"year","titration",{"dividedDoses":5,"titration":64},{"start":40,"increment":40,"incrementEveryDays":65,"targetMin":48,"targetMax":48,"max":48},7,[67],{"source":34,"section":68},"2.1",[70],{"text":71,"refs":74},{"fa":72,"en":73},"در عدم تحمل تا ۵ mg کاهش. پیش از شروع سابقه دوقطبی بررسی شود.","May reduce to 5 mg if not tolerated. Screen for bipolar disorder before starting.",[75,76],{"source":34,"section":68},{"source":34,"section":77},"2.2",[79],{"id":80,"severity":81,"text":82,"refs":85},"ci","block",{"fa":83,"en":84},"حساسیت؛ MAOI همزمان، ظرف ۱۴ روز پس از قطع MAOI یا ۲۱ روز پس از قطع وورتیوکستین؛ لینزولید یا متیلن بلو وریدی.","Hypersensitivity; MAOIs, within 14 days of stopping an MAOI or 21 days of stopping vortioxetine; linezolid or IV methylene blue.",[86],{"source":34,"section":87},"4",[89],{"text":90,"refs":93},{"fa":91,"en":92},"هشدار جعبه‌ای: افزایش افکار و رفتار خودکشی در کودکان و جوانان؛ در کودکان تأیید نشده.","Boxed warning: increased suicidal thoughts and behaviour in children and young adults; not approved in children.",[94],{"source":34,"section":95},"Boxed Warning",[],[],[],{"status":100,"reviewer":101,"date":101},"unverified",null,[103],{"regimen":54,"formulation":37,"input":104,"expect":107},{"ageYears":105,"weightKg":106},35,70,{"perDose":40,"tabletsPerDoseRounded":5},[109],"N06AX26",{"status":111,"refs":112},"not-found",[113],{"source":114,"section":115,"url":116},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Vortioxetine",{"kind":118,"refs":119,"id":122},"NDA",[120],{"source":34,"section":121},"SPL approval \u002F marketing category","NDA204447",[124,127,131,134],{"kind":125,"url":126,"label":122},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=204447",{"kind":128,"url":129,"label":130},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6-1ca97145e838","FDA Trintellix",{"kind":132,"url":133,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614003.html",{"kind":135,"url":136,"label":109},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06AX26",{"pregnancy":138,"lactation":147,"pediatric":155,"geriatric":163},{"level":139,"text":140,"quote":143,"refs":144},"caution",{"fa":141,"en":142},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on data from published observational studies, exposure to SSRIs or SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions (5.3) and Clinical Considerations ] .",[145],{"source":34,"section":146},"8.1",{"level":139,"text":148,"quote":151,"refs":152},{"fa":149,"en":150},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of vortioxetine in human milk, the effects on the breastfed infant, or the effects on milk production.",[153],{"source":34,"section":154},"8.2",{"level":156,"text":157,"quote":160,"refs":161},"avoid",{"fa":158,"en":159},"هشدار جعبه‌ای برچسب درباره کودکان.","Boxed warning in the label about children.","Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies.",[162],{"source":34,"section":95},{"level":139,"text":164,"quote":167,"refs":168},{"fa":165,"en":166},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Serotonergic antidepressants have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.7) ] .",[169],{"source":34,"section":170},"8.5",1792115199522]